Soligenix publishes HyBryte™ clinical summary

Soligenix, Inc. has announced the publication of a clinical summary for its HyBryte™ therapy in the journal 'Expert Opinion on Investigational Drugs.' This publication details the findings from the company's late-stage biopharmaceutical development efforts. The summary provides valuable insights into the potential of HyBryte™ as a therapeutic agent, contributing to the scientific understanding and potential commercialization pathway for the drug.